The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer

This publication has 15 references indexed in Scilit:

• Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours
  British Journal of Cancer, 1998
• Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity
  Cancer, 1997
• Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
  Anti-Cancer Drugs, 1996
• Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy.
  Journal of Clinical Oncology, 1994
• Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide
  Cancer, 1994
• Overcoming tumor necrosis factor-α resistance of human renal and ovarian carcinoma cells by combination treatment with buthionine sulfoximine and tumor necrosis factor-α. Role of tumor necrosis factor-α mRNA down-regulation in tumor cell sensitization
  Cancer, 1994
• Effect of Glutathione and its Related Enzymes on Chemosensitivity of Renal Cell Carcinoma and Bladder Carcinoma Cell Lines
  Journal of Urology, 1994
• Prophylactic oral UFT therapy for superficial bladder cancer
  Cancer, 1993
• Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.
  Journal of Clinical Investigation, 1988
• Early intravesical instillation of adriamycin with oral administration of 5-fluorouracil after transurethral resection for superficial bladder cancer: preliminary results
  Cancer Chemotherapy and Pharmacology, 1987